US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Circio Holding ASA: Requested Conversion of Convertible Bonds

Reference is made to Circio Holding ASA's (the "Company") outstanding convertible bonds as issued to Atlas Special Opportunities, LLC ("Atlas") under the Investment Agreement entered into between Atlas and the Company in March 2023. Atlas has, by a notice of conversion, requested conversion of convertible bonds with a nominal value of NOK 2,000,000. Pursuant to the bond terms, the conversion price is NOK 0.5935. As the conversion price cannot be set lower than the nominal value of the share, the conversion price for the conversion is set to NOK 0.6 and the NOK 2,000,000 convertible bonds

TG01 mutant RAS cancer vaccine data showing clinical benefit in multiple myeloma presented at EHA 2025

· 12 of 20 patients have already been enrolled in the study; excellent safety profile of TG01 vaccination confirmed · TG01 vaccination led to an increase in mutant RAS T-cells in 6 patients; 5 of these patients remain on study with stable disease · Genetic characteristics of patients mechanistically support the observed immune responses and clinical benefit, and propose novel biomarkers for patient selection in future trials · Circio’s strategy to develop TG01 through external collaborations continues to demonstrate success alongside its core circular RNA programOslo, Norway, 16

Circio Holding ASA: Minutes from the annual general meeting 2025

Oslo, 5 June 2025: Circio Holding ASA (the “Company”) held its annual general meeting today, 5 June 2025, as a physical meeting at the Company’s offices at Universitetsgata 2, 0164 Oslo. All resolutions were made in accordance with the proposals from the board of directors and the nomination committee, including, but not limited to, approval of the 2024 annual accounts and the approval of authorizations to the board of directors. The minutes from the annual general meeting are attached hereto and will also be made available on the Company’s website circio.com/investors/general-

Circio Holding ASA: Requested Conversion of Convertible Bonds

Reference is made to Circio Holding ASA's (the "Company") outstanding convertible bonds as issued to Atlas Special Opportunities, LLC ("Atlas") under the Investment Agreement entered into between Atlas and the Company in March 2023. Atlas has, by a notice of conversion, requested conversion of convertible bonds with a nominal value of NOK 2,500,000. Pursuant to the bond terms, the conversion price is NOK 0.5893. As the conversion price cannot be set lower than the nominal value of the share, the conversion price for the conversion is set to NOK 0.6 and the NOK 2,500,000 convertible bonds

Circio presents new and differentiating circVec data and corporate update in live webcast

· Significant advantage of circVec confirmed in vivo for therapeutically relevant AAV variants and DNA formats · Distinct expression biology positions circular RNA expression systems as a novel alternative for diseases where current approaches are less suitable · Early data shows 10-fold increase in potency for circVec AAV in heart, opening development opportunities in cardiac genetic diseaseOslo, Norway 28 May 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, announces it is hosting a

Circio Holding ASA – Updated information to the notice of annual general meeting 2025 – Reverse share split and share capital decrease

Oslo, 27 May 2025: Reference is made to the notice of the annual general meeting of Circio Holding ASA (the "Company") published on 15 May 2025 and the annual general meeting ("AGM") to be held on Thursday 5 June 2025 at 10:00 hours (CEST). The board of directors has resolved to withdraw the proposals under agenda item 10 "Reverse Share Split" and agenda item 11 "Share Capital Decrease". Consequently, agenda item 10 and agenda item 11 will not be subject to voting at the AGM. In addition, the board of directors proposes that the previously proposed board authorizations in agenda items

Circio invites to R&D and corporate update webcast on 28 May 2025

· CTO Dr. Thomas B Hansen will present a summary of recent in vivo results validating circVec performance in novel AAV and DNA formats for gene and cell therapy · CEO Dr. Erik D Wiklund will provide a corporate and business development update, incl.  information related to the upcoming annual general meetingOslo, Norway 22 May 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, invites to a live webcast at 10:00am CEST on Wednesday 28 May 2025. In the webcast, CTO Dr. Thomas B Hansen will

Circio Holding ASA – Notice of annual general meeting 2025

Oslo, 15 May 2025: The annual general meeting of Circio Holding ASA (the “Company”) will be held on Thursday 5 June 2025 at 10:00 hours (CEST) as a physical meeting at the Company’s offices at Universitetsgata 2, 0164 Oslo. The notice and agenda of the annual general meeting is attached hereto, including further information on advance voting, power of attorney and physical participation. The notice and the nomination committees recommendation, and the documents referred to therein are made available on the Company’s webpage www.circio.com under the heading “Investors”.

Circular RNA innovator Circio presents strengthened circVec gene therapy data at ASGCT 2025

· New and strengthened circVec in vivo expression data presented for both viral and non-viral vector formats · circVec demonstrates a distinct pattern of expression in vivo compared to equivalent mRNA-based vectors · The data confirms the potential of circVec as a powerful expression system for cell and gene therapy, indicating novel opportunities to target tissues and diseases where conventional gene therapy technology is unsuitableOslo, Norway 14 May 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic

Circio Holding ASA: Requested Conversion of Convertible Bonds

Reference is made to Circio Holding ASA's (the "Company") outstanding convertible bonds as issued to Atlas Special Opportunities, LLC ("Atlas") under the Investment Agreement entered into between Atlas and the Company in March 2023. Atlas has, by a notice of conversion, requested conversion of convertible bonds with a nominal value of NOK 2,500,000 which, pursuant to the bond terms, are convertible into 3,931,847 new shares in the Company at a conversion price of NOK 0.6358. The Company's share capital will accordingly be increased by NOK 2,359,108.20 by the issuance of 3,931,847 new

Circular RNA innovator Circio to present strengthened circVec gene therapy data at ASGCT 2025

· Circio will present new and strengthened circVec in vivo proof-of-concept data at the American Society of Gene and Cell Therapy (ASGCT) annual meeting · The poster presentation will take place on 13 May 2025 in New Orleans, USA · ASGCT is considered the most prestigious and widely attended international conference in the gene and cell therapy fieldOslo, Norway 6 May 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, today announces that it will present new and strengthened circVec

Circio Holding ASA: Requested Conversion of Convertible Bonds

Reference is made to Circio Holding ASA's (the "Company") outstanding convertible bonds as issued to Atlas Special Opportunities, LLC ("Atlas") under the Investment Agreement entered into between Atlas and the Company in March 2023. Atlas has, by a notice of conversion, requested conversion of convertible bonds with a nominal value of NOK 2,000,000. Pursuant to the bond terms, the conversion price is NOK 0.5677. As the conversion price cannot be set lower than the nominal value of the share, the conversion price for the conversion is set to NOK 0.6 and the NOK 2,000,000 convertible bonds

Circio Holding ASA: Requested Conversion of Convertible Bonds

Reference is made to Circio Holding ASA's (the "Company") outstanding convertible bonds as issued to Atlas Special Opportunities, LLC ("Atlas") under the Investment Agreement entered into between Atlas and the Company in March 2023. Atlas has, by a notice of conversion, requested conversion of convertible bonds with a nominal value of NOK 2,000,000. Pursuant to the bond terms, the conversion price is NOK 0.5256. As the conversion price cannot be set lower than the nominal value of the share, the conversion price for the conversion is set to NOK 0.6 and the NOK 2,000,000 convertible bonds

Circio Holding ASA: Annual Report 2024 - Correction to ESEF-file name

Oslo, Norway, 11 April 2025 – Reference is made to the Annual Report, including European Single Electronic Format (ESEF), published today 11 April 2025. This stock exchange notice is issued due to a change in the file name of the ESEF report. The complete version of the Annual Report, including the Auditor’s Report and the approved version in the European Single Electronic Format (ESEF), is attached to this stock exchange notice and is also available on the Company’s website: www.circio.com/en/financial-reports/.

Circio Holding ASA: Annual Report 2024

Oslo, Norway, 11 April 2025 – Reference is made to the press release published on 10 April 2025, regarding the Board of Directors of Circio Holding ASA having approved the Company's Annual Report, including the financial statements for 2024. The complete version of the Annual Report, including the Auditor’s Report and the approved version in the European Single Electronic Format (ESEF), is being published today and made available on the Company's website, www.circio.com/en/financial-reports/.

Circio Holding ASA: Annual Report 2024

Oslo, Norway 10 April 2025 - the Board of Directors of Circio Holding ASA today approved the Company's Annual Report, including the financial statements for 2024, which will be subject to approval by the Company's Annual General Meeting (AGM) to be held on 5 June 2025. The 2024 Annual Report is attached to this press release. A version including the Auditors Report and in the European Single Electronic Format (ESEF), will be published and made available on the Company's website, www.circio.com, tomorrow 11 April 2025.

Circio Holding ASA: Requested Conversion of Convertible Bonds

Reference is made to Circio Holding ASA's (the "Company") outstanding convertible bonds as issued to Atlas Special Opportunities, LLC ("Atlas") under the Investment Agreement entered into between Atlas and the Company in March 2023. Atlas has, by a notice of conversion, requested conversion of convertible bonds with a nominal value of NOK 1,500,000. Pursuant to the bond terms, the conversion price is NOK 0.52. As the conversion price cannot be set lower than the nominal value of the share, the conversion price for the conversion is set to NOK 0.6 and the NOK 1,500,000 convertible bonds

Entos Pharmaceuticals and Circio initiate collaboration to test novel platform for circVec circular RNA delivery

· Circio´s durable circVec DNA vectors will be combined with the Entos Fusogenix PLV delivery technology · The combination is expected to enhance circVec DNA vector delivery efficiency and reduce toxicity compared to LNP-formulations · The combined technologies can allow future joint development of novel, potent, repeat-dosable therapeutic candidates for genetic medicine, chronic disease, and vaccinesOslo, Norway, Edmonton, Canada and London, United Kingdom, 3 April 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next

Circio presents R&D and corporate update in live webcast

· The latest circVec 3.0 generation of its circular RNA therapeutic platform technology has now been validated in multiple vector formats · New delivery data demonstrates efficient delivery to the spleen, opening novel circVec opportunities in cell therapy · Rich pipeline of upcoming R&D milestones, including several existing and new research collaborations · Presentation of 2024 financial results, including ongoing activities to strengthen Circio´s financial positionOslo, Norway 26 March 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular

Circio invites to corporate update webcast on 26 March 2025

· CEO Dr. Erik D Wiklund will provide a general company update and present the most recent circVec experimental data and R&D strategy · CFO Dr. Lubor Gaal will present the 2024 financial results (unaudited) and provide an update on Circio´s corporate development activitiesOslo, Norway 19 March 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, invites to a live webcast at 10:00am CET on Wednesday 26 March 2025. In the webcast, Circio management will provide a corporate update and present

Circio Holding ASA – Funding requested under financing commitment from Atlas

Oslo, Norway 14 March 2025: Reference is made to Circio Holding ASA's (the "Company") stock exchange announcement on 29 May 2024, regarding the financing commitment provided by Atlas to fund the Company´s operations until the end of June 2025 (the “Financing Commitment”). The Company has by a notice of exercise under the Agreement and the Financing Commitment requested Atlas to subscribe and pay for one additional tranche of convertible bonds, consisting of 8 convertible bonds with an aggregate principal amount equal to NOK 4,000,000. Atlas will be allocated these bonds under the terms

Circio presents results that further validate the circVec circular RNA platform at two international industry conferences

Oslo, Norway 5 March 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, today announces that CEO Dr. Erik Digman Wiklund and CSO Dr. Victor Levitsky are presenting updated data demonstrating the significant advantages of Circio’s circular RNA circVec platform compared to current mRNA-based vector technology. The data further strengthens the in vitro and in vivo validation of Circio’s platform. The presentations are being delivered at two major biopharma industry conferences in Basel, Switzerland,

Circio´s leading position in circular RNA therapeutics highlighted by continued broad coverage in international life science industry media

· More than 50 articles and interviews featuring Circio management have been published in the past year in over 30 widely read EU and US life science publications, with a combined readership of 14 million · Circio was invited to publish a comprehensive review article in Nature Reviews Genetics summarizing the therapeutic potential of circular RNA  · Interviews with CEO Dr Erik Digman Wiklund featured in three prominent biotech industry podcastsOslo, Norway, 3 March 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe